Department of Oncology, University of Cambridge

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

Retrieved on: 
금요일, 2월 10, 2023
Translational research, General Hospital, Breast cancer, IND, Pancreatic cancer, McGill University Health Centre, Hospital, Medical research, Department of Oncology, University of Cambridge, Sunlight, Squamous cell carcinoma, Jewish General Hospital, Research, Uterine sarcoma, Pharmaceutical industry, Cancer

The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies.

Key Points: 
  • The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies.
  • At any time the research results become conclusive and Sunshine Biopharma wishes to proceed to conducting a Phase I clinical trial, the Jewish General Hospital is prepared to negotiating a new agreement to define the responsibilities and obligations of the parties for such Phase I clinical trial to be performed.
  • The research will be conducted under the direction of Dr. Gerald Batist, Head of the Department of Oncology at the Jewish General Hospital and Director of the McGill Center for Translational Research in Cancer (MCTRC) based at the Lady Davis Institute for Medical Research.
  • “The Jewish General Hospital is one of the leading cancer centers in North America and we are delighted to work with their world renowned oncology physician and research scientist, Dr. Gerald Batist,” said Dr. Steve Slilaty CEO of Sunshine Biopharma.

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Retrieved on: 
수요일, 12월 7, 2022
Roche, Bristol Myers Squibb, University, Immunotherapy, Liver, Colorectal cancer, Head, Melanoma, Sarcoma, Clinical trial, CPS, CD40L, RP1, Osteosarcoma, CRC, Hepatocellular carcinoma, SCCHN, SOC, RP2, Uveal melanoma, Chondrosarcoma, Principal investigator, Skin cancer, Neck, CR, ORR, GM-CSF, Radiation, Department of Oncology, University of Cambridge, Bevacizumab, Nivolumab, Disease, Safety, Cancer, RP3, Liver disease, PR, CSCC, Patient, HCC, Medical imaging, Pharmaceutical industry, Vaccine

WOBURN, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical. The IGNYTE clinical trial is evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab, with the anti-PD1 failed melanoma cohort being conducted with registrational intent. The Company also provided new data from the ongoing Phase 1 clinical trials evaluating RP2 and RP3, as well as a detailed overview of its RP2/3 Phase 2 development plans. A virtual investor event will be held today at 8:00 a.m. ET to discuss the new data. The data from this update can be found in the presentation for today’s investor event, linked here.

Key Points: 
  • The IGNYTE clinical trial is evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab, with the anti-PD1 failed melanoma cohort being conducted with registrational intent.
  • The Company is today presenting new data from the first 75 patients from the 125 patient anti-PD1 failed melanoma cohort, which has registrational intent.
  • The IGNYTE clinical trial is being conducted under a collaboration and supply agreement with Bristol-Myers Squibb, with the anti-PD1 failed melanoma cohort expected to complete enrollment by around the end of this year.
  • This cohort was initiated after completing enrollment in a prior Phase 2 cohort in the same clinical trial of approximately 30 patients with melanoma.

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

Retrieved on: 
목요일, 12월 1, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, AstraZeneca, Natural killer T cell, Adenosine, Euronext Paris, Immune system, Pharmacokinetics, Antibody, Sanofi, Cancer, Novo Nordisk, Clinic, CD39, Partnership, Patient, Tumor microenvironment, Oncology, UNIL, Trastuzumab, Department of Oncology, University of Cambridge, IPHA, ESMO, Lung cancer, Neoplasm, IPC, ATP, IPH, Bristol Myers Squibb, Congress, Durvalumab, Immunity, European Society for Medical Oncology, Safety, Vaccine, Pharmaceutical industry, MD, Intrinsic and extrinsic properties

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.
  • IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment.
  • By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

Retrieved on: 
수요일, 10월 26, 2022
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, PARP, BTK, Therapy, CLL, Tislelizumab, Degenerative disease, Chronic lymphocytic leukemia, NASDAQ, Patient, Research, Twitter, Jazz Pharmaceuticals, Technology, Private Securities Litigation Reform Act, Goal, Pharmacovigilance, Company, Marketing, MCL, Novartis, Pharmacokinetics, SSE, Urology, Safety, Intellectual property, Department of Oncology, University of Cambridge, Bristol Myers Squibb, Lymphoid leukemia, COVID-19, Half-life, Global health, Pharmaceutical industry, Vaccine, Union, Oncology, Adium, Hematology, BeiGene

The announcement of regulatory approvals for BRUKINSA in Latin America follows a recent positive CHMP Opinion for BRUKINSA as a treatment for chronic lymphocytic leukemia (CLL) in the European Union.

Key Points: 
  • The announcement of regulatory approvals for BRUKINSA in Latin America follows a recent positive CHMP Opinion for BRUKINSA as a treatment for chronic lymphocytic leukemia (CLL) in the European Union.
  • BRUKINSA was specifically designed to deliver targeted and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
  • BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs.
  • Adium provides its partners a full set of local capabilities including commercial, market access, regulatory and pharmacovigilance.

Amberstone Biosciences Announces Formation of Scientific Advisory Board

Retrieved on: 
월요일, 6월 27, 2022
Department, Massachusetts Institute of Technology, Sidney Kimmel Comprehensive Cancer Center, University of California, Irvine School of Medicine, Patient, MD–PhD, Biotechnology, PE, Research, Precision medicine, Doctor of Science, Engineering, Johns Hopkins School of Medicine, Upside Foods, Tumor microenvironment, Department of Oncology, University of Cambridge, Cancer, Memorial Sloan Kettering Cancer Center, Pharmacology, Genentech, Therapy, University, Pancreatic cancer, Doctor of Philosophy, Amgen, Drug development, Leadership, Immunology, Johns Hopkins, Multimedia, Pharmaceutical industry, Management, Amber

LAGUNA HILLS, Calif., June 27, 2022 /PRNewswire/ -- Amberstone Biosciences ( www.amberstonebio.com ), an emerging biotech company with expertise in developing a new generation of cancer therapeutics, is announcing the formation of a scientific advisory board comprised of industry leaders in drug delivery, oncology, immunology and pharmaceutical sciences.

Key Points: 
  • LAGUNA HILLS, Calif., June 27, 2022 /PRNewswire/ -- Amberstone Biosciences ( www.amberstonebio.com ), an emerging biotech company with expertise in developing a new generation of cancer therapeutics, is announcing the formation of a scientific advisory board comprised of industry leaders in drug delivery, oncology, immunology and pharmaceutical sciences.
  • The board will work closely with Amberstone to advance the company's therapeutic programs based on its Tumor Microenvironment Activated Therapeutics (T-MATE) platform.
  • "Each member of our scientific advisory board brings deep expertise in critical areas for drug development," said Dr. George Wu, chief executive officer of Amberstone.
  • The members of the Amberstone board include:
    Robert Langer, ScD, is an institute professor at the Massachusetts Institute of Technology.

Oncopole, FRQS cancer division, announces the winners of its "Priorité patient" 2022 Competition

Retrieved on: 
월요일, 6월 13, 2022
MSD, Loma Linda University School of Public Health, Department of Nutrition, Lung, Enrique Dussel, Animal, Multiple myeloma, Policy, Universitate metro station, Chemoradiotherapy, Aeschynite-(Y), MSSS, Breast, Public, Medicine, Health, Cancer, Center, Anesthesiology, CHUM, CHU, Hypnosis, Partnership, Virtual reality, Part, SSA, Cardiovascular disease, Quality of life, Obesity, Population, HIV, Investor, Heart, Merck, Foreign policy, Department of Oncology, University of Cambridge, MEI, Survivor, School, Vaccine, Prostate, Patient, Association belge des Consommateurs Test-Achats ASBL v Conseil des ministres, Infection, Department, Dysphagia, Life, Head, Program, Research, Science, Intervention, YouTube, Unit, Haematopoietic system, Emotion, Risk, Anatomical pathology, SAN, Sherbrooke, Fonds, Pharmaceutical industry, Dentistry

This competition provides financial support for research projects aimed at improving the care and services for people living with cancer in Quebec.

Key Points: 
  • This competition provides financial support for research projects aimed at improving the care and services for people living with cancer in Quebec.
  • This competition is carried out in collaboration with the Unit de soutien au systme de sant apprenant (SSA) Qubec and the Programme qubcois de cancrologie of the MSSS.
  • The context of the pandemic has highlighted the lack of emotional support for people affected by cancer.
  • Chemoradiotherapy treatments are known to produce significant side effects in people treated for head and neck cancer often leading to swallowing disorders or dysphagia.

Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China

Retrieved on: 
월요일, 6월 6, 2022
Leadership, Entrepreneurship, Shanghai East Hospital, Department of Oncology, University of Cambridge, Prospection, Sop's Arm, OF, PPC, Partnership, ASCO, City, Surrogate endpoint, Plasma protein binding, ASIA, Growth, Cancer, Cros, Acquisition, Compliance, Incidence, DCT, Clinical trial, Department, Drug development, Ethernet Global Data Protocol, Asia-Pacific, NCGS, CRO, CAGR, KLOS, Medical imaging, Pharmaceutical industry, Fine chemical

With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs."

Key Points: 
  • With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs."
  • According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5*, over the past 5 years the growth of oncology trials (CAGR of 25%) in China outpaced other countries.
  • Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.
  • Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally.

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Retrieved on: 
금요일, 6월 3, 2022
Biotechnology, General Health, Health, Oncology, Radiation, XELOX, Immunotherapy, Adult, Large-cell lung carcinoma, Liver cancer, Trastuzumab, Shanghai East Hospital, Capecitabine, Research, Survival, Lancet, Checkmate, Toxicity, Fundamental, LinkedIn, Progression-free survival, Annual report, Mesothelioma, Forward-looking statement, Glioblastoma, Alternating electric field therapy, Private Securities Litigation Reform Act, Stomach cancer, Department of Oncology, University of Cambridge, Toxic leukoencephalopathy, Pancreatic cancer, Ovarian cancer, U.S. Securities and Exchange Commission, Stomach, Shanghai Tongji University School of Medicine, Patient, Infection, Trial of the century, Health, COVID-19, Safety, Incidence, Lists of diseases, NASDAQ, Twitter, Department, Overalls, Degenerative disease, Oxaliplatin, Neoplasm, Skin, Cancer, Medical imaging, Pharmaceutical industry

The addition of Tumor Treating Fields to standard-of-care chemotherapy could lead to impactful changes in the treatment of gastric cancer patients and I look forward to confirming these data in additional clinical studies.

Key Points: 
  • The addition of Tumor Treating Fields to standard-of-care chemotherapy could lead to impactful changes in the treatment of gastric cancer patients and I look forward to confirming these data in additional clinical studies.
  • Gastric cancer is the third leading cause of cancer deaths worldwide and the third leading cause of cancer deaths in China.
  • One of the most commonly used chemotherapy regimens for treating gastric cancer is XELOX, a combination of oxaliplatin and capecitabine.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

St. Jude research highlighted at annual meeting of the American Society of Clinical Oncology

Retrieved on: 
화요일, 5월 31, 2022
Department, Brain, The Ride to Conquer Cancer, Children's Oncology Group, Hospital, Social media, Developmental Neurobiology, Survival, Cancer, World, Patient, Pediatrics, Treatment, American Society of Clinical Oncology, Society, Survival rate, NCI-designated Cancer Center, Cell, Genetics, Research, Global health, National Cancer Institute, Aircraft pilot, CST, Child, List, Global Oncology, ASCO, Neuroblastoma, Life, Department of Oncology, University of Cambridge, Childhood cancer, St. Jude Children's Research Hospital, McCormick Place, Medicine, Medulloblastoma

MEMPHIS, Tenn., May 31, 2022 /PRNewswire/ -- Professionals from St. Jude Children's Research Hospital will share original research and expertise at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting will be held June 4–8, at McCormick Place in Chicago and include online lectures.

Key Points: 
  • Learn best practices and hear insights from St. Jude Children's Research Hospital oncologists, psychologists, scientists and more at the annual gathering of clinical oncology experts.
  • MEMPHIS, Tenn., May 31, 2022 /PRNewswire/ -- Professionals from St. Jude Children's Research Hospital will share original research and expertise at the American Society of Clinical Oncology (ASCO) annual meeting.
  • ASCO is the premier professional society for clinical oncology, representing nearly 45,000 individuals dedicated to cancer care.
  • Amar Gajjar , M.D., Department of Pediatric Medicine and Department of Oncology chair, will receive the 2022 ASCO Pediatric Oncology Award .

RSNA: MRI Finds Lung Abnormalities in Non-Hospitalized Long COVID Patients

Retrieved on: 
화요일, 5월 24, 2022
Xenon, Linda, Employment, Department, Death, Education, University of Texas Health Science Center Department of Radiology, Blood, Doctor of Philosophy, Department of Oncology, University of Cambridge, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Hospital, One Oxford Centre, Infection, Patient, Radiological Society of North America, MRI, COVID19, Health, Association, COVID-19, DRS, University, RSNA, PHC, Research, Grist, Brain, Carbon, Ventilation, OAK, SCI, Public health, Breathe Me, Trust, Society, Lung, FAN, Radiation, M.A, COVID, University of Wisconsin School of Medicine and Public Health, Fatigue, Medical imaging, Pharmaceutical industry, Animal, Radiology

OAK BROOK, Ill., May 24, 2022 /PRNewswire-PRWeb/ -- A special type of MRI found lung abnormalities in patients who had previously had COVID-19, even those who had not been hospitalized with the illness, according to a new study published May 24 in the journal Radiology.

Key Points: 
  • The presence of ongoing symptoms related to prior COVID-19 infection is known as post-COVID-19 condition, or long COVID.
  • Long COVID presents a global health burden, with many people unable to return to normal activities or employment months after becoming unwell.
  • In long COVID, a breathing pattern disorder is commonly identified and contributes to breathlessness in a significant proportion of patients.
  • "Lung Abnormalities Depicted by Hyperpolarized Xenon MRI in Patients with Long COVID."